{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:35Z","timestamp":1753891775414,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes from this viral infection due to the immunosuppression brought about by the underlying cancer and the effects of therapy. We present a 55-year-old woman diagnosed with relapsed\/refractory Hodgkin\u2019s lymphoma (HL) who had been heavily pretreated with multiagent chemotherapy, autologous hematopoietic stem cell transplantation (autoHCT), allogeneic hematopoietic stem cell transplantation (alloHCT) and was complicated with EBV associated posttransplant lymphoproliferative disease (PTLD) and chronic graft-versus-host-disease (GVHD). The patient was recently treated with brentuximab and donor lymphocyte infusion (DLI) for relapse after alloHCT. She suffered from severe COVID-19 pneumonia and eventually succumbed to acute respiratory distress syndrome (ARDS) and multiorgan failure. Of note, this is the first reported case of COVID-19 in a HL patient who was being treated with brentuximab for relapse after alloHCT.<\/jats:p>","DOI":"10.3389\/fonc.2021.601709","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T08:38:26Z","timestamp":1616056706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed\/Refractory Hodgkin\u2019s Lymphoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Ipek","family":"Yonal-Hindilerden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fehmi","family":"Hindilerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metban","family":"Mastanzade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik Onur","family":"Tiryaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevim","family":"Tasan-Yenigun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selcuk","family":"Aksoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif Atahan","family":"Cagatay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliha","family":"Nalcaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"Research T: A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/344899","article-title":"Respiratory virus infections in adults with hematologic malignancies: a prospective study","volume":"36","author":"Martino","year":"2003","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcv.2015.04.012","article-title":"The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients","volume":"68","author":"Hakki","year":"2015","journal-title":"J Clin Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS COV-2: a multi-center study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discovery"},{"article-title":"People who are at higher risk for severe illness","volume-title":"Coronavirus Dis 2019 (COVID-19)","year":"2020","key":"B6"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2367","article-title":"Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment","volume":"6","author":"Abid","year":"2020","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16798","article-title":"Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2","volume":"190","author":"O\u2019Kelly","year":"2020","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003144","article-title":"Incidental Discovery of a COVID-19 Infection on a Reevaluation FDG PET\/CT in a Patient Treated for Hodgkin Lymphoma","volume":"45","author":"Simand","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"E631","DOI":"10.1503\/cmaj.200831","article-title":"Incidental COVID-19 on PET\/CT imaging","volume":"192","author":"Amin","year":"2020","journal-title":"CMAJ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003143","article-title":"18F-FDG PET\/CT in Hodgkin Lymphoma With Unsuspected COVID-19","volume":"45","author":"Boulvard Chollet","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137244","article-title":"Clinical\u00a0and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3323","article-title":"High CD30 ligand expression by epithelial cells and Hassal\u2019s corpuscles in the medulla of human thymus","volume":"91","author":"Romagnani","year":"1998","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02354.x","article-title":"Deciphering CD30 ligand biology and its role in humoral immunity","volume":"118","author":"Kennedy","year":"2006","journal-title":"Immunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31755","article-title":"Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation:\u00a0A\u00a0report from the EBMT Lymphoma Working Party","volume":"125","author":"Bazarbachi","year":"2019","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMp2006588","article-title":"Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19","volume":"382","author":"Lewis","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0832-y","article-title":"Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases","volume":"34","author":"von Lilienfeld-Toal","year":"2020","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12435","article-title":"Phase I\u00a0\/\u00a0II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma","volume":"105","author":"Ogura","year":"2014","journal-title":"Cancer Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01294","article-title":"Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline","volume":"11","author":"Abid","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.601709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T08:38:29Z","timestamp":1616056709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.601709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":25,"alternative-id":["10.3389\/fonc.2021.601709"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.601709","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"article-number":"601709"}}